XML 126 R63.htm IDEA: XBRL DOCUMENT
v3.25.1

Trade receivables and other current assets - Additional Information (Details) - EUR (€) € in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Disclosure of Trade Receivables and Other Current Assets [Line Items] |  |  |
Trade receivables | € 2,977 | € 905 |
Prepaid expenses | 3,195 | 2,560 |
Decrease in other receivables | (1,459) | (4,375) | € (4,215)
Payments to suppliers for goods and services | 700 | 1,100 |
Research tax credit | 3,300 | 3,900 |
Janssen |  |  |
Disclosure of Trade Receivables and Other Current Assets [Line Items] |  |  |
Trade receivables | 2,100 |  |
Supplier |  |  |
Disclosure of Trade Receivables and Other Current Assets [Line Items] |  |  |
Decrease in other receivables | 300 |  |
Master Service Agreement | Janssen |  |  |
Disclosure of Trade Receivables and Other Current Assets [Line Items] |  |  |
Trade receivables |  | 500 |
2023 Tax Year |  |  |
Disclosure of Trade Receivables and Other Current Assets [Line Items] |  |  |
Research tax credit | 3,400 |  |
2023 Tax Year | Nanobiotix S.A. |  |  |
Disclosure of Trade Receivables and Other Current Assets [Line Items] |  |  |
Research tax credit |  | 3,762 |
Research tax credit | 3,000 |  |
2023 Tax Year | Curadigm SAS |  |  |
Disclosure of Trade Receivables and Other Current Assets [Line Items] |  |  |
Research tax credit |  | 177 |
Research tax credit | 400 |  |
2022 Tax Year |  |  |
Disclosure of Trade Receivables and Other Current Assets [Line Items] |  |  |
Research tax credit |  | 4,000 |
2022 Tax Year | Nanobiotix S.A. |  |  |
Disclosure of Trade Receivables and Other Current Assets [Line Items] |  |  |
Research tax credit |  | 3,800 |
2022 Tax Year | Curadigm SAS |  |  |
Disclosure of Trade Receivables and Other Current Assets [Line Items] |  |  |
Research tax credit |  | 200 |
Third Party Services |  |  |
Disclosure of Trade Receivables and Other Current Assets [Line Items] |  |  |
Prepaid expenses | 1,100 |  |
Clinical Products |  |  |
Disclosure of Trade Receivables and Other Current Assets [Line Items] |  |  |
Prepaid expenses | 600 |  |
Technology Transfer and Technical | Janssen |  |  |
Disclosure of Trade Receivables and Other Current Assets [Line Items] |  |  |
Trade receivables | 700 |  |
Intellectual Property Services | Janssen |  |  |
Disclosure of Trade Receivables and Other Current Assets [Line Items] |  |  |
Trade receivables | 100 |  |
LianBio, NBTXR3 |  |  |
Disclosure of Trade Receivables and Other Current Assets [Line Items] |  |  |
Trade receivables |  | 300 |
MD Anderson Cancer Center, NBTXR3 |  |  |
Disclosure of Trade Receivables and Other Current Assets [Line Items] |  |  |
Prepaid expenses | € 1,200 | € 1,200 |

X
- Definition The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_CurrentPrepaidExpenses
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of current trade receivables. [Refer: Trade receivables] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 68 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_68&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 78 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_CurrentTradeReceivables
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow to suppliers for goods and services. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 7 -IssueDate 2024-01-01 -Paragraph 14 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_14_c&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_PaymentsToSuppliersForGoodsAndServices
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Adjustments For Decrease (Increase) In Other Receivables + References No definition available. + Details
Name: | nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Current Receivables From Taxes Other Than Income Tax, Income Tax Credit + References No definition available. + Details
Name: | nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncomeTaxCredit
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Disclosure of Trade Receivables and Other Current Assets + References No definition available. + Details
Name: | nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems
Namespace Prefix: | nbx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research Tax Credit + References No definition available. + Details
Name: | nbx_ResearchTaxCredit
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=nbx_JanssenPharmaceuticaNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nbx_ResearchOrganizationCROAndToClinicalServicesProvidersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_ContractNameAxis=nbx_MasterServiceAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_OpenTaxYearAxis=nbx_A2023TaxYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nbx_NanobiotixSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nbx_CuradigmSASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_OpenTaxYearAxis=nbx_A2022TaxYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nbx_ThirdPartyServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nbx_ClinicalProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nbx_TechnologyTransferAndTechnicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nbx_IntellectualPropertyServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_CollaborationAgreementAxis=nbx_MDAndersonCancerCenterNBTXR3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |